# Acadia Pharmaceuticals

Type: Company (ACAD)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/acadia-pharmaceuticals
Canonical HTML page: https://getbiobrief.com/entity/acadia-pharmaceuticals

## Timeline

- **2026-03-19**: Earnings Call — Management hosts a conference call to discuss 2025 performance and 2026 outlook.
- **2026-03-18**: Financial Reporting — XOMA files Q4 and Full Year 2025 financial results with the SEC.
- **2026-02-25**: Q4 Earnings Call — ACADIA reports strong year-end results and 2026 guidance.
- **2026-02-02**: Asset Acquisition — Completion of a significant acquisition of royalty rights from a clinical-stage partner.
- **2026-01-12**: Strategic Disclosure — XOMA issues Regulation FD disclosure regarding portfolio updates.
- **2025-11-15**: Daybue Stix Launch — Launch of the granule formulation to enhance patient compliance.
- **2023-03-10**: Daybue Approval — FDA approves Daybue as the first treatment for Rett syndrome.
- **2016-05-01**: Nuplazid Approval — FDA approves Nuplazid for Parkinson's disease psychosis.

## Recent coverage (4 stories)

### XOMA Royalty Reports Q4 Results as Portfolio Scaling Drives Long-Term Value
2026-03-19 15:43:47 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

XOMA Royalty reported its Q4 and full-year 2025 financial results, highlighting a significant expansion of its royalty portfolio and the continued commercial success of key assets like Vabysmo and Daybue. The company remains focused on its strategic pivot toward becoming a pure-play royalty aggregator in the biotechnology sector.
Full story: https://getbiobrief.com/story/xoma-royalty-q4-2025-earnings-analysis

### Parental Demand for Off-Label Autism Treatments Outpaces Clinical Evidence
2026-03-16 12:50:54 · Sentiment: Neutral · Impact: 6/10 · Sources: 17

A surge in parental demand for off-label treatments for autism spectrum disorder (ASD) has created a significant rift between families and the medical community. While anecdotal reports drive interest in therapies like GLP-1s and Rett syndrome drugs, physicians cite a lack of robust clinical data and potential safety risks as reasons for their reluctance to prescribe.
Full story: https://getbiobrief.com/story/autism-treatment-demand-vs-clinical-evidence

### ACADIA Pharmaceuticals Solidifies Rare Disease Leadership in Q4 Results
2026-02-27 12:48:03 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

ACADIA Pharmaceuticals delivered a strong Q4 performance, underscored by the rapid adoption of Daybue and the resilience of its Parkinson’s franchise. The results highlight a successful transition into a diversified commercial-stage biotech with a clear path to sustained profitability.
Full story: https://getbiobrief.com/story/acadia-pharmaceuticals-q4-2025-earnings-analysis

### Rare Disease Commercialization and M&A Drive Mid-Cap Biotech Growth
2026-02-26 00:13:15 · Sentiment: Positive · Impact: 7/10 · Sources: 20

Mid-cap biotech and specialty pharma companies are demonstrating strong commercial maturation, led by record-breaking rare disease revenues and strategic consolidation. Key players like Mirum and Acadia are scaling rapidly, while Alkermes’ acquisition of Avadel signals a shift toward aggressive portfolio expansion in the neuroscience space.
Full story: https://getbiobrief.com/story/biotech-pharma-earnings-analysis-q4-2025

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.